These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26921342)

  • 1. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.
    Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA
    Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
    Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
    Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration.
    Muralidharan R; Babu A; Amreddy N; Basalingappa K; Mehta M; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
    J Nanobiotechnology; 2016 Jun; 14(1):47. PubMed ID: 27328938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.
    Lin GL; Ting HJ; Tseng TC; Juang V; Lo YL
    PLoS One; 2017; 12(10):e0185625. PubMed ID: 28968471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttranscriptional Regulation of the Inflammatory Marker C-Reactive Protein by the RNA-Binding Protein HuR and MicroRNA 637.
    Kim Y; Noren Hooten N; Dluzen DF; Martindale JL; Gorospe M; Evans MK
    Mol Cell Biol; 2015 Dec; 35(24):4212-21. PubMed ID: 26438598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells.
    Techasintana P; Davis JW; Gubin MM; Magee JD; Atasoy U
    PLoS One; 2015; 10(7):e0129321. PubMed ID: 26162078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymer-based delivery of RNA-based therapeutics in ovarian cancer.
    Weirauch U; Gutsch D; Höbel S; Aigner A
    Methods Mol Biol; 2013; 1049():443-65. PubMed ID: 23913237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HuR Promotes Ovarian Cancer Cell Proliferation by Regulating TIMM44 mRNA Stability.
    Yu X; Li Y; Ding Y; Zhang H; Ding N; Lu M
    Cell Biochem Biophys; 2020 Dec; 78(4):447-453. PubMed ID: 32901414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth
    Muralidharan R; Babu A; Amreddy N; Srivastava A; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
    Mol Cancer Ther; 2017 Aug; 16(8):1470-1486. PubMed ID: 28572169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
    Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
    Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.
    Guo Y; Tian P; Yang C; Liang Z; Li M; Sims M; Lu L; Zhang Z; Li H; Pfeffer LM; Yue J
    Pharm Res; 2015 Mar; 32(3):769-78. PubMed ID: 25823356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of novel small molecule disruptors of HuR-mRNA interaction.
    Wu X; Lan L; Wilson DM; Marquez RT; Tsao WC; Gao P; Roy A; Turner BA; McDonald P; Tunge JA; Rogers SA; Dixon DA; Aubé J; Xu L
    ACS Chem Biol; 2015 Jun; 10(6):1476-84. PubMed ID: 25750985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA OIP5-AS1/cyrano sponges RNA-binding protein HuR.
    Kim J; Abdelmohsen K; Yang X; De S; Grammatikakis I; Noh JH; Gorospe M
    Nucleic Acids Res; 2016 Mar; 44(5):2378-92. PubMed ID: 26819413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia.
    Gauchotte G; Hergalant S; Vigouroux C; Casse JM; Houlgatte R; Kaoma T; Helle D; Brochin L; Rech F; Peyre M; Labrousse F; Vallar L; Guéant JL; Vignaud JM; Battaglia-Hsu SF
    J Pathol; 2017 Aug; 242(4):421-434. PubMed ID: 28493484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.
    Erkinheimo TL; Lassus H; Sivula A; Sengupta S; Furneaux H; Hla T; Haglund C; Butzow R; Ristimäki A
    Cancer Res; 2003 Nov; 63(22):7591-4. PubMed ID: 14633672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.
    Mehta M; Basalingappa K; Griffith JN; Andrade D; Babu A; Amreddy N; Muralidharan R; Gorospe M; Herman T; Ding WQ; Ramesh R; Munshi A
    Oncotarget; 2016 Oct; 7(40):64820-64835. PubMed ID: 27588488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.
    Zhu H; Berkova Z; Mathur R; Sehgal L; Khashab T; Tao RH; Ao X; Feng L; Sabichi AL; Blechacz B; Rashid A; Samaniego F
    Mol Cancer Res; 2015 May; 13(5):809-18. PubMed ID: 25678597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment.
    Amreddy N; Babu A; Panneerselvam J; Srivastava A; Muralidharan R; Chen A; Zhao YD; Munshi A; Ramesh R
    Nanomedicine; 2018 Feb; 14(2):373-384. PubMed ID: 29155362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
    Hijaz M; Das S; Mert I; Gupta A; Al-Wahab Z; Tebbe C; Dar S; Chhina J; Giri S; Munkarah A; Seal S; Rattan R
    BMC Cancer; 2016 Mar; 16():220. PubMed ID: 26979107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.